Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform.

Ranjit S. Bindra,Ranjini K. Sundaram,Robert J. Aiello,Dan Marshall,Patricia Bourassa,Johanna Csengery,Qing Zhang,Brett Robinson,Lori Lopresti-Morrow,Jane Bechtold,Laurie A. Tylaska,Tim Paradis,Vishwas M. Paralkar,Per Hellsund,Peter M. Glazer

Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform.

2019

Ranjit S. Bindra
Ranjini K. Sundaram
Robert J. Aiello
Dan Marshall
Patricia Bourassa
Johanna Csengery
Qing Zhang
Brett Robinson
Lori Lopresti-Morrow
Jane Bechtold
Laurie A. Tylaska
Tim Paradis
Vishwas M. Paralkar
Per Hellsund
Peter M. Glazer

e14664Background: Poly(ADP-ribose)polymerase inhibitors (PARPi’s) are a promising new class of anti-cancer agents, but their clinical application has largely been limited to tumors with homologous ...

Keywords:

PARP inhibitor
Cancer research
Pathology
Medicine
tumor targeting
Homologous chromosome
Polymerase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations